Vaccine Update (5/3/21)
Beginning May 6th, vaccines will be given at Archbold Corporate Care Center located at 2705 E Pinetree Blvd, Suite A, by appointment only. To schedule an appointment, please call 229.584.SHOT, Monday through Friday, 9am to 4pm beginning May 3.
Archbold is currently administering the Pfizer vaccine to all adults and children 16 & 17 with a parent or guardian present.
2nd dose Pfizer vaccines will still be administered at the walk-in clinic at Archbold Memorial Hospital until May 21st.
Please print and fill out the COVID-19 Vaccine Consent Form and bring it with you to your scheduled appointment.
If your organization/business is interested in scheduling an on-site vaccine clinic, please click the button below and fill out the form.
COVID-19 Vaccine Information
There are three COVID-19 vaccines currently authorized and recommended for use in the United States. We are hopeful this is a huge step forward in our fight against COVID-19 and we will work hard to administer vaccines to those that want one while also carefully following federal and state guidelines regarding who should be vaccinated first.
The CDC currently recommends giving the COVID-19 vaccine in phases due to the US supply being limited at this time. According to the CDC, their recommendations are based on those from the Advisory Committee on Immunization Practices (ACIP), an independent panel of medical and public health experts.
Archbold began rolling out vaccines to frontline healthcare workers as recommended by the State of Georgia in January. Effective March 15, 2021, we have been given guidance to expand phase IA of the rollout plan.
Please see below for more detailed information regarding the vaccines.
- COVID-19 vaccines are being held to the same safety standards as all other vaccines.
- The vaccines received FDA Emergency Use Authorizations (EUAs).
- Approval of a vaccine for use in people involves multiple phases with different goals for assessing effectiveness and safety in different populations. There are a total of 4 phases and the vaccine must meet very intense safety criteria before completing each phase. Once a vaccine is approved for use after phase 3, it has been tested in tens of thousands of people and if no significant harmful side effects are noted, it is considered safe for use. Phase 4 involves continued monitoring and gathering of safety data. This type of clinical trial has been used for decades to approve medications and vaccines.
- FDA requires 50% efficacy of a COVID-19 vaccine – the COVID-19 vaccines are showing 94-95% efficacy in preventing COVID-19 during these trials.
- The vaccines sent to Archbold are mRNA vaccines with a 2-dose schedule.
- The vaccines have been tested in diverse adult populations, including older adults and communities of color.
- For the latest information about authorized vaccines, please click here.
Emergency Use Authorizations (EUAs)
- The issuance of an EUA is different than an FDA approval (licensure) of a vaccine. In determining whether to issue an EUA for a product, the FDA evaluates the available evidence and assesses any known or potential risks and any known or potential benefits, and if the benefit-risk assessment is favorable, the product is made available during the emergency.
- For more information about the COVID-19 EUAs, please click here
What are messenger RNA (mRNA) vaccines?
- mRNA vaccines carry genetic material that teaches our cells how to make a harmless piece of “spike protein,” which is found on the surface of the SARS-CoV-2 virus.
- Genetic material from the vaccine is destroyed by our cells once copies of the spike protein are made and it is no longer needed.
- Cells display this piece of spike protein on their surface, and an immune response is triggered inside our bodies. This produces antibodies to protect us from getting infected if the SARS-CoV-2 virus enters our bodies.
Specific COVID-19 mRNA Vaccine
- These mRNA vaccines are expected to produce side effects after vaccination, especially after the 2nd dose. Possible side effects may include:
- Muscle aches
- No significant safety concerns were identified in the clinical trials. COVID-19 vaccines were tested in large clinical trials to make sure they meet safety standards. Many people were recruited to participate in these trials to see how the vaccines offer protection to people of different ages, races, and ethnicities, as well as those with different medical conditions.
- The mRNA COVID-19 vaccine cannot give you COVID-19 and does not contain live or killed viral particles.
- For more information regarding mRNA vaccines, please click here.
Storage and Distribution
- Archbold has the capacity to store the COVID vaccines in an ultra-cold freezer and has a distribution plan in place in order to keep the vaccine at the correct temperature while administering.
- Even when people receive the vaccine they will not be immediately protected and will need to continue to wear masks, social distance, and practice frequent hand hygiene.
- The Pfizer and Moderna vaccines will require 2 shots, with a few weeks between each shot, and protection will usually occur about 2 weeks after the second shot.
- Even when you receive your vaccine, most people around you may have not. It is still possible to transmit the disease to others until the vaccine is widely used. Wearing a mask, social distancing, and practicing hand hygiene protects those who have not been vaccinated, especially residents in long-term care facilities.
- It is safe to get the vaccine even if you have had COVID-19 and have antibodies. The additional protection will not cause harm and can increase your protection from future COVID-19 infections.
- For frequently asked questions, please click here.